← Back to Search

Radiation Therapy

Hypofractionated Radiotherapy for Diffuse Intrinsic Pontine Glioma

N/A
Waitlist Available
Led By Luke E Pater, MD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have a diagnosis of progressive DIPG.
Received prior IMRT based definitive radiotherapy to a dose of ≥54 Gy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

This trial is testing if a lower dose of radiation over a shorter period of time is just as effective as the standard dose for treating a certain type of brain tumor.

Eligible Conditions
  • Diffuse Intrinsic Pontine Glioma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with a type of brain tumor called progressive DIPG.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Post Radiation Toxicity
Secondary outcome measures
Change in Quality of Life score
Overall Survival
Progression Free Survival
+2 more

Side effects data

From 2012 Phase 2 trial • 17 Patients • NCT00983307
71%
Rash
53%
Death
41%
Diarrhea
41%
Fatigue
35%
Bilirubin Increased
29%
Nausea
24%
Elevated Hemoglobin
18%
Creatinine increased
18%
Pain
18%
Dyspnea
18%
Dry skin
18%
Esophagitis
18%
Glucose, serum-high
12%
Constipation
12%
Myositis
12%
Dyspnea w/ADL
12%
Sodium, serum-low
12%
Lymphopenia
12%
Dysphagia
12%
Pneumonitis
12%
Anorexia
12%
Dermatitis
12%
Dry eye
12%
Edema
12%
Hypokalemia
12%
Tremor
6%
Blurred vision
6%
Mucositis
6%
Alopecia
6%
Blepharitis
6%
Magnesium
6%
Decreased hearing in left ear
6%
Elevated Glucose
6%
Alkaline Phosphatase
6%
Peripheral neuropathy
6%
Severe pain (back)
6%
Renal failure
6%
Dysgeusia
6%
Dyspepsia
6%
Platelets
6%
Pruritis
6%
Dehydration
6%
Headache
6%
Vomiting
6%
Mucositis/Stomatitis
6%
Hyperkalemia
6%
Muscle weakness, generalized
6%
Dizziness
6%
dysmorphic nail bed
6%
Fever
6%
Elevated Heart Rate
6%
Hypocalcemia
6%
Hyponatremia
6%
Hypoxia
6%
Vaginal Infection
6%
Joint pain
6%
Upper respiratory infection
6%
Vaginal dryness and irritation
6%
White Blood Cells in Urine
6%
Weight loss
6%
Cough
100%
80%
60%
40%
20%
0%
Study treatment Arm
Erlotinib and Radiotherapy

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hypofractionated RadiotherapyExperimental Treatment1 Intervention
15 Gy given in 3 fractions over 2 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hypofractionated Radiotherapy
2009
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

Children's Hospital Medical Center, CincinnatiOTHER
813 Previous Clinical Trials
6,531,537 Total Patients Enrolled
6 Trials studying Diffuse Intrinsic Pontine Glioma
1,679 Patients Enrolled for Diffuse Intrinsic Pontine Glioma
University of CincinnatiLead Sponsor
427 Previous Clinical Trials
634,366 Total Patients Enrolled
Luke E Pater, MDPrincipal InvestigatorUniversity of Cincinnati

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still available for this research project?

"Unfortunately, this clinical trial is not accepting participants at the current moment. This research was first posted on January 31st 2018 and was last updated July 1 2021; however, there are 1323 other similar opportunities for prospective enrollees across various sites."

Answered by AI
Recent research and studies
~1 spots leftby Mar 2025